Merck's Victrelis still lags Incivek despite improvement in Europe
This article was originally published in Scrip
Merck & Co's Victrelis has upped its market share in the battle of the protease inhibitors, but it still lags a long way behind Vertex Pharmaceuticals/Janssen's Incivek/Incivo. Victrelis (boceprevir) has grown its share to over 40% in the US (compared with around 25% in autumn last year) and even exceeded 50% in some markets, including France, Germany, Canada, Norway and Denmark, according to Merck's head of global human health, Adam Schechter.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.